IP_AC/001/2563 February 24, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited
, 2020 Subject Management’ discussion and analysis for the fiscal year ended December 31, 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited ( “ the Company” ) would like
- Translation - Page 1 of 6 CBG 042/2017 11 August 2017 Subject Management discussions and analysis for the 3-month and 6-month periods ending 30 June 2017 To President The Stock Exchange of Thailand
President The Stock Exchange of Thailand Reference is made to the resolutions of the Board of Director Meeting No. 6/2017 of Carabao Group Public Company Limited (the "Company") held on 11 August 2017 as
- Translation - Page 1 of 6 CBG 052/2017 14 November 2017 Subject Management discussions and analysis for the 3-month and 9-month periods ending 30 September 2017 To President The Stock Exchange of
) EBITDA and EBITDA margin was THB 977mn and 14.0%, respectively, surging by 578.0% or THB 833mn, largely as a result of the aforementioned reasons above and lower loss on impairment of assets Reported net
effectively. Consequently, we recorded Bt5,251mn in revenue, growing 26% YoY. Soften EBITDA from cost pressure AIS EBITDA in FY22 was Bt89,731mn, dropped -1.8%YoY mostly from a surging electricity price and
cost. EBITDA in 3Q22 was Bt22,091mn dropped -3.5%YoY mostly from resumed marketing spending and surging network OPEX due to higher utility price and network expansion. It dropped -1.2% QoQ due to core